Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 7 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du
acheter cialis original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.
Microsoft word - 458643d3-03c8-085ec8.doc
World Anti-Doping Code 2007 Prohibited List
The World Anti-Doping Code 2007 Prohibited List is effective from 1 January 2007.
The World Anti-Doping Agency (WADA) reviews the Prohibited List every year to ensure the
details of the substances and methods prohibited in sport are consistent with scientific and
technological developments. Changes in 2007 Prohibited List include:
• Beta-2 agonists – Salbutamol
A Salbutamol concentration of greater than 1000 ng/ml will be considered an Anti-Doping Rule Violation (at this level Salbutamol will not be considered a Specified Substance). If an athlete sample reveals a concentration of greater than 1000 ng/ml and that athlete has an Abbreviated Therapeutic Use Exemption (ATUE), the athlete will need to prove that the level of Salbutamol is due to therapeutic use of inhaled Salbutamol. This applies to samples collected both In-Competition and Out-of Competition.
• Diuretics and other Masking Agents
Further explanation has been provided, with the additional wording – ‘and other substances with similar biological effect(s)
’ has been added to clarify that substances not listed as examples are also prohibited.
Additional examples of stimulants have been added to the list of prohibited substances.
Athletes are reminded that the Prohibited List includes examples of substances
prohibited; additional products with similar chemical structure or biological effect are also
prohibited. A product does not have to be listed by name to be prohibited.
To provide further guidance on the requirements of Therapeutic Use or Abbreviated
Therapeutic Use applications, additional examples of routes of administration for the use
of glucocorticosteroids have been included. A route of administration reference table for
the use of glucocorticosteroids is included in this issue of the Anti-Doping Update.
• Substances prohibited in specific sports
Chess has removed Beta-Blockers from their list of prohibited substances and billiards
has removed alcohol.
• Specified substances
The presence of salbutamol above 1000 ng/ml in a sample will not be considered a
specified substance. Tuaminoheptane has been added as an example of a specified
The 2007 Prohibited List, Summary of Major Modifications, and details of the Monitoring List
can be downloaded from the WADA website www.wada-ama.org. What is a specified substance?
The Prohibited List may identify specified substances which are susceptible to unintentional
Anti-Doping Rule Violations, because of their general availability for medical purposes or are
less likely to be abused as doping agents. Examples of specified substances include Beta-2
agonists (inhaled asthma medications) and glucocorticosteroids.
Complete details of specified substances are included on the 2007 Prohibited List www.wada-
Athletes are reminded to re-check the status of all medications each year, in accordance with
any revisions made to the prohibited List.
The 2007 Prohibited List – an overview
The World Anti-Doping Code 2007 Prohibited List is an International Standard; it is applicable
to all athletes around the globe who compete in a sport that complies with the World Anti-
Doping Code (the Code). Substances and methods prohibited at all times - In-Competition and Out-of-
• agents with anti-estrogenic activity
Substances and methods prohibited In-Competition
• glucocorticosteroids – dependant on the route of administration. For further
information please refer to the ASADA website www.asada.gov.au or cal the ASADA Anti-Doping Hotline 1800 020 506.
Substances prohibited in particular sports
Athletes are advised to check the 2007 Prohibited List or their sports anti-doping policy. The 2007 Monitoring Program
In accordance with the Code, WADA monitors the use of a list of substances that are not on
the Prohibited List in order to detect the possible misuse of these substances.
The 2007 Monitoring Program includes the use of some stimulants, for example caffeine and
pseudoephedrine and for narcotics – reviewing the morphine/codeine ratio. The 2007
Monitoring Program is based on samples collected In-Competition only.
For further details of the 2007 Monitoring Program please refer to the WADA website
www.wada-ama.org. Important advice for athletes.
ASADA advises athletes to re-check the status of any medication in accordance with the 2007
Prohibited List. A product that was permitted in the past may now be prohibited. Athletes can
check medications by calling the ASADA Anti-Doping Hotline 1800 020 506, or refer to the
ASADA website www.asada.gov.au.
Glucocorticosteroids – routes of administration table
Types of medications and
Route of administration
applications for use
Intravenous injections or infiltration administered in
effect (e.g.: shock) or as a replacement therapy in adrenocortical insufficiency Injection into soft tissue for
inflammation Electrical current is used to drive glucocorticosteroids
(methylprednisolone) Kenacort – A10 (triamcinolone)
Unexpected high serum levels of tacrolimus aftera single topical application in an infantResearch Institute for Environmental Health at the Heinrich-Topical tacrolimus has been found to be effective andsafe for the treatment of atopic dermatitis in adults andSupported by the Elterninitiative Kinderkrebsklinik e. V., Du¨sseldorf, andchildren.We report an infant with severe combinedDeutsche
IngentaConnect Post-dexamethasone cortisol correlateswith severity of depression. during carbamazepine treatment in women Authors: Osuch, Elizabeth A.1; Cora-Locatelli, Gabriela2; Frye, Mark A.3; Huggins, Teresa2; Kimbrell, Timothy A.4; Ketter, Terence A.5; Callahan, Ann M.2; Post, Robert M.2 Source: Acta Psychiatrica Scandinavica, Volume 104, Number 5, November 2001 , p